# ILLUMENATE Pivotal Post-Approval Study (PAS)

Study · id `cardio:ct-nct03421561` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03421561](<https://clinicaltrials.gov/study/NCT03421561>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03421561

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.

## Technical summary

Registry record NCT03421561. Randomized; double masking; primary purpose treatment. Start 2013-06-18 (actual); primary completion 2017-12-08 (actual). Results posted on 2024-02-02.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 300 participants (enrolled count; ClinicalTrials.gov record NCT03421561, source copy `cardio:ctgov-nct03421561-2024-02-02`, retrieved 2026-10-31)
- Started: 2013-06-18 (actual) (ClinicalTrials.gov record NCT03421561, source copy `cardio:ctgov-nct03421561-2024-02-02`, retrieved 2026-10-31)
- Primary completion: 2017-12-08 (actual) (ClinicalTrials.gov record NCT03421561, source copy `cardio:ctgov-nct03421561-2024-02-02`, retrieved 2026-10-31)
- Completion: 2020-10-06 (actual) (ClinicalTrials.gov record NCT03421561, source copy `cardio:ctgov-nct03421561-2024-02-02`, retrieved 2026-10-31)
- Results first posted: 2024-02-02 (ClinicalTrials.gov record NCT03421561, source copy `cardio:ctgov-nct03421561-2024-02-02`, retrieved 2026-10-31)
- Countries: United States; Austria (ClinicalTrials.gov record NCT03421561, source copy `cardio:ctgov-nct03421561-2024-02-02`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03421561-2024-02-02`, retrieved 2026-10-31)

## The registry's words

- Brief title: ILLUMENATE Pivotal Post-Approval Study (PAS)
- Condition: Peripheral Artery Disease
- Intervention (Device): Stellarex 0.035" OTW Drug-coated Angioplasty Balloon
- Intervention (Device): EverCross™ 0.035 PTA Balloon Catheter
- Lead sponsor: Spectranetics Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: Spectranetics Corporation (`cardio:org-spectranetics-corporation`)

## Provenance

Content hash: 7df519459d20474f711bb59910a63be9f268df69b02cce2f664a47aafe41963a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
